Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR1 | Q9BXC0 | 3/20 | 0.33 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.33 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3421751 | 0.79 | ALDH1A1 (0.47) | HCAR1CSNK2A1 | |
| SCHEMBL24878849 | 0.79 | HTR2A (0.31) | — | |
| SCHEMBL7045265 | 0.79 | HTR3E (0.47) | HCAR1 | |
| SCHEMBL659974 | 0.79 | MAPT (0.40) | HCAR1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL11762285 | 0.75 | NPC1 (0.34) | HCAR1 | |
| SCHEMBL7044222 | 0.75 | HCAR1 (0.33) | HCAR1 | |
| SCHEMBL5738369 | 0.75 | CACNA1H (0.36) | HCAR1 | |
| SCHEMBL7045388 | 0.75 | NPSR1 (0.44) | CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL66296 | 0.74 | NOS1 (0.44) | CYP2A6 | |
| SCHEMBL7043132 | 0.74 | GRIN2D (0.39) | CYP3A4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114903848-A | Transdermal preparation | 阿根塔创新有限公司 | 2022-08-16 | — | — | CN | disclosed |
| CN-109549927-B | Solid solution compositions and their use in cardiovascular disease | 因佛斯特医疗有限公司 | 2022-03-29 | — | — | CN | disclosed |
| CN-113038937-A | Palatable antiparasitic formulations | 硕腾服务有限责任公司 | 2021-06-25 | — | — | CN | disclosed |
| CN-111295376-A | Injectable isoxazoline pharmaceutical compositions and their use against parasite infestations | 英特维特国际股份有限公司 | 2020-06-16 | — | — | CN | disclosed |
| US-20120270827-A1 | Indole Antiviral Compositions And Methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-10-25 | — | — | US | disclosed |
| US-8202844-B2 | Indole antiviral compositions and methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-06-19 | — | — | US | disclosed |
| US-20110178038-A1 | Indole Antiviral Compositions And Methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-07-21 | — | — | US | disclosed |
| US-7928080-B2 | Indole antiviral compositions and methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-04-19 | — | — | US | disclosed |
| US-7625871-B2 | Indole antiviral compositions and methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-12-01 | — | — | US | disclosed |
| US-20090281052-A1 | Indole Antiviral Compositions And Methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-11-12 | — | — | US | disclosed |
| US-7419963-B2 | Indole antiviral compositions and methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-09-02 | — | — | US | disclosed |
| US-20080146517-A1 | Indole Antiviral Compositions And Methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-06-19 | — | — | US | disclosed |
| EP-1677784-A1 | INDOLE ANTIVIRAL COMPOSITIONS AND METHODS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2006-07-12 | — | — | EP | disclosed |
| EP-1671972-A1 | Octahydropyrrolo[3,4-c]pyrrole derivatives | Pfizer Limited (GB) | 2006-06-21 | — | — | EP | disclosed |
| US-20050143329-A1 | Indole antiviral compositions and methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2005-06-30 | — | — | US | disclosed |
| WO-2005034943-A1 | INDOLE ANTIVIRAL COMPOSITIONS AND METHODS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2005-04-21 | — | — | WO | disclosed |
| WO-2004047769-A2 | BENZIMIDAZOLES AND ANALOGS THEREOF AS ANTIBACTERIALS | ISIS PHARMACEUTICALS, INC. (US) | 2004-06-10 | — | — | WO | disclosed |
| WO-1994008456-A1 | POLYSUBSTITUTED BENZIMIDAZOLES AS ANTIVIRAL AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1994-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281052-A1 | Indole Antiviral Compositions And Methods | IDO1, IDO2, MAVS | HCAR1 1708/4885CSNK2A2 855/4885CSNK2B 829/4885 |
| US-20120270827-A1 | Indole Antiviral Compositions And Methods | IDO1, IDO2, MAVS | HCAR1 1708/4885CSNK2A2 855/4885CSNK2B 829/4885 |
| US-20080146517-A1 | Indole Antiviral Compositions And Methods | IDO1, IDO2, MAVS | HCAR1 1708/4885CSNK2A2 855/4885CSNK2B 829/4885 |
| US-20050143329-A1 | Indole antiviral compositions and methods | IDO1, IDO2, MAVS | HCAR1 1708/4885CSNK2A2 855/4885CSNK2B 829/4885 |
| US-20110178038-A1 | Indole Antiviral Compositions And Methods | IDO1, IDO2, MAVS | HCAR1 1708/4885CSNK2A2 855/4885CSNK2B 829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.